Vigabatrin for the Treatment of Cocaine Dependency
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
Sponsor: Catalyst Pharmaceuticals, Inc.
A PHASE2/PHASE3 clinical study on Cocaine Addiction and Cocaine Dependence, this trial is completed. The trial is conducted by Catalyst Pharmaceuticals, Inc. and has accumulated 6 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2_PHASE3
First recorded
Jan 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Catalyst Pharmaceuticals, Inc.
- National Institute on Drug Abuse (NIDA)
- VA Office of Research and Development
For direct contact, visit the study record on ClinicalTrials.gov .